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The HIV epidemic in South Africa (SA) has had a substantial 
impact on healthcare services, particularly in the public sector. 
This is also true for the laboratory services owing to the increased 
burden of pathology in the community and the demand for therapy 
monitoring. The impact on haematology services is singularly 
notable because of the numerous haematological complications of 
HIV infection, which occur secondary to effects of the virus itself, 
as a result of associated opportunistic infections/malignancies, or as 
adverse drug effects.[1] Several studies have reported the prevalence 
of haematological complications in HIV-seropositive patients,[2-7] 
with variables such as disease stage and exposure to antiretroviral 
therapy (ART) being important determinants.[8] However, there 
is a paucity of published SA data in this regard, despite the fact 
that the burden of HIV infection in SA is among the highest in 
the world.[9] Documenting the SA experience in this respect is 
important, as the prevalence of some cytopenias has been shown 
to vary geographically, with anaemia being more prevalent among 
treatment-naive patients with AIDS from Africa than among those 
from Asia or the Americas.[5] Furthermore, geographical differences 
have been reported within Africa, with the prevalence of anaemia 
in patients with immunological AIDS (iAIDS) being 32.2%, 49.3% 
and 58.0% in Rwanda,[6] Uganda[7] and Nigeria,[4] respectively. The 
prevalence of cytopenias in SA patients is therefore of interest.
Objectives
(i) To document the prevalence of cytopenias in full blood counts 
(FBCs) from HIV-positive patients in a large academic state sector 
laboratory serving a community with a high HIV prevalence; and 
(ii) to indirectly gauge the impact of the HIV epidemic on the state 
sector haematology laboratory services by determining the HIV 
seropositivity rate among samples submitted for an FBC. Because 
the FBC is the most commonly performed test in the haematology 
laboratory, the seropositivity rate among samples submitted for 
an FBC serves as a surrogate marker of the overall burden of HIV 
infection on the haematology services.
Methods
FBCs submitted to the National Health Laboratory Service (NHLS) 
laboratory at Chris Hani Baragwanath Academic Hospital (CHBAH), 
Soweto, Johannesburg, on 7 non-consecutive days throughout 
2012 were extracted from the laboratory information system (LIS) 
(DisaLab version 04.16.04.373; Laboratory System Technologies, SA) 
and retrospectively reviewed. To ensure that the data were repre-
sentative of all sites serviced by the laboratory, the 7 days sampled 
included every day of the week, and to avoid temporal bias with 
regard to cytopenia prevalence (as a result of seasonal diseases 
affecting blood counts), every season of the year was represented. All 
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(haemoglobin <8 g/dL) in 32/307 (10.4%). Multivariate linear regression analysis showed significant independent associations between the 
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the HIV-positive patients, respectively, with no statistically significant association between either of these cytopenias and iAIDS, exposure 
to ART or VL.
Conclusions. The findings reflect the substantial impact of the HIV epidemic on state sector laboratory resources, particularly the 
haematology service.
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the FBCs performed on each randomly selected day were extracted, 
pooled and then listed randomly through sorting the samples 
alphabetically by the first letter of the patient’s name. This yielded 
4 456 FBCs, of which the first 1 020 were sampled for analysis. 
The LIS repository for the included samples was then reviewed for 
relevant HIV test results where available, and the presence of any 
cytopenia/s was recorded. The samples included specimens collected 
from inpatient, outpatient and casualty facilities at CHBAH, as well 
as primary healthcare (PHC) clinics in Soweto. Anaemia in adults 
was defined as a haemoglobin (Hb) concentration <14 g/dL in males 
and <12 g/dL in females. For children, anaemia was defined as an 
Hb concentration below the age-specific reference ranges. Moderate 
and severe anaemia were defined as an Hb concentration <10 g/dL 
and <8 g/dL, respectively, for all age groups. Thrombocytopenia was 
defined as a platelet count <150 × 109/L, neutropenia as an absolute 
neutrophil count <2 × 109/L and lymphopenia as a lymphocyte count 
below the age-specific reference range. The mean cell volume (MCV) 
was classified as low, normal or high based on age-specific laboratory 
reference ranges. Other information recorded from the LIS (where 
available) included demographic details, recent CD4 counts and HIV 
viral loads (VLs), as well as information pertaining to ART exposure. 
iAIDS was defined as a CD4 count <200 cells/µL in adults, and as a 
CD4 count <200 cells/µL or a CD4 percentage <15% in children aged 
>5 years, <15% in children aged 36 - 59 months, <20% in children 
aged 12 - 35 months and <25% in children aged <11 months. The 
study was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand, Johannesburg (ref. no. M131025).
Statistical analysis
Statistical analysis was performed using Statistica software, version 
12.0 (StatSoft, USA). Continuous data are presented as medians with 
interquartile ranges (IQRs) and categorical data as frequencies and 
percentages. The Mann-Whitney U-test was used to compare variables 
of interest. Multivariate linear regression analysis was performed to assess 
the relationship between anaemia, thrombocytopenia and neutropenia 
and various variables of interest. Where continuous data were not 
normally distributed, variables were log-transformed before regression 
analysis. For patients with an undetectable VL, the low detection limit 
was used for the purposes of statistical analysis. The reported adjusted 
beta coefficients are the antilog values of the calculated coefficients. 
Residual analysis was performed on all statistically significant results, 
and any data point with a standard residual of >2.5 was excluded from 
analysis. Blood counts in patients treated with different antiretroviral 
agents were compared by Kruskal-Wallis one-way analysis of variance 
followed by post hoc multiple comparisons of the mean rank scores 
between pairs of groups with a Bonferroni adjustment. Statistical 
signiﬁcance was accepted at a p-value of <0.05.
Results
HIV prevalence
A total of 1 020 FBCs were extracted from the laboratory database, 
14 of which were excluded from further analysis because they were 
repeat specimens collected on the same day. Of the remaining 1 006 
samples, 212 (21.7%) were collected at PHC clinics around Soweto, 
543 (54.0%) from the casualty department, wards or intensive care 
units (ICUs) of CHBAH, and the remainder (25.0%) from the hospital 
outpatient departments. HIV status was documented in 561 patients 
(55.8%), of whom 307 (54.7%) were HIV-positive. Test results were 
most frequently available for patients seen in medical wards, the 
haematology/oncology departments and outpatient/PHC facilities 
(the latter probably owing to the large proportion of samples received 
from these sites for the purposes of ART monitoring) (Table 1). Close 
to one-third of the HIV-positive patients were inpatients, the greatest 
proportion of whom were admitted to medical wards (46.9%), while 
<10% were admitted to ICUs, obstetrics/gynaecology wards and 
paediatric wards. Within the major hospital disciplines, the HIV 
seropositivity rate was highest in the medical wards (close to 60%), 
lowest in the paediatric units (<20%), and ~28 - 40% in the other 
departments assessed (Table 1). Pertinent demographic and HIV-
related details of the HIV-positive patients are summarised in Table 2.
Cytopenia prevalences
Cytopenia/s were present in 194/307 (63.2%) of the patients. An 
isolated cytopenia was present in 157/194 (80.9%), while 32/194 
(16.5%) and 5/194 (2.6%) had bi- and pancytopenia, respectively. 
A significantly larger proportion of patients with one or more 
cytopenia/s had iAIDS compared with those without any cytopenia 
(52.7% (77/146) v. 17.5% (17/97); p<0.0001). In contrast, the 
proportions of patients on ART did not differ significantly between 
those with and without cytopenias (79.0% (79/100) v. 88.3% (68/77); 
p=0.1). Cytopenias were significantly more common among in patients 
(p<0.0001), with >90% of inpatients having one or more cytopenia/s 
as opposed to <50% of outpatients (Table 1).
Anaemia analysis
Among the HIV-positive patients, 183/307 (59.6%) had anaemia 
(median Hb 11.6 g/dL), which was severe in 32/307 (10.4%). Anaemia 
was significantly more common in HIV-positive adult males than in 
HIV-positive adult females (p=0.047), being present in 70/99 males 
(70.7%) v. 101/176 females (57.4%) (median Hb 12.3 g/dL (IQR 8.80 - 
14.33) v. 11.5 g/dL (IQR 9.63 - 12.68), respectively). Among HIV-
positive adults, the CD4 count was significantly lower in individuals 
with anaemia than in those with normal Hb concentrations (median 
CD4 count 159 cells/µL v. 400 cells/µL, respectively; p<0.0001), but 
did not differ between HIV-positive adult males and females with 
anaemia (median CD4 count 164 cells/µL v. 177 cells/µL, respectively; 
p=0.785). Among the HIV-positive children and adolescents, only 
12/31 (38.7%) had anaemia (median Hb 11.3 g/dL).
Both anaemia and severe anaemia were significantly more 
prevalent among inpatients than outpatients (p<0.0001), with a 
particularly high rate of severe anaemia among the HIV-positive 
patients admitted to medical wards (35.6%). Further information 
regarding the prevalence of anaemia among HIV-positive patient 
subgroups is summarised in Table 3.
Multivariate linear regression analysis showed significant inde-
pendent associations between the presence of anaemia and both 
iAIDS (adjusted beta coefficient 0.41; standard error (SE) 0.10; 
p<0.0001) and male sex (adjusted beta coefficient 0.196; SE 0.09; 
p<0.025), while no significant relationship was found between 
anaemia and exposure to ART (p=0.70), VL (p=0.33) or age (p=0.14). 
Severe anaemia was significantly inversely related to exposure to ART 
on multivariate linear regression analysis (adjusted beta coefficient 
–0.32; SE 0.15; p=0.035), but was not associated with the presence 
of iAIDS (p=0.16), sex (p=0.68), age (p=0.97) or VL (p=0.66). A 
Bonferroni-adjusted Kruskal-Wallis analysis showed no significant 
difference in the Hb concentration between patients treated with the 
various antiretroviral regimens (Fig. 1).
The median MCV was 91.1 fL (IQR 83.2 - 98.3), and the MCV 
was low, normal and high in 36/307 (11.7%), 198/307 (64.5%) 
and 70/307 (22.8%), respectively, of the HIV-positive patients. Of 
the patients with macrocytosis, normocytosis and microcytosis, 
28/70 (40.0%), 43/198 (21.7%) and 33/36 (91.7%), respectively, 
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had anaemia. The median MCV and the 
prevalence of microcytic anaemia did not 
differ statistically between males and females 
(median MCV 90.7 fL v. 91.2 fL; p=0.94 
and microcytic anaemia prevalence 12.5% v. 
9.4%; p=0.85).
Thrombocytopenia analysis
Among the HIV-positive patients, the 
median platelet count was 254 × 109/L 
(IQR  204 - 324). Thrombocytopenia  was 
present in 37/307 (12.1%), with 20 (54.5%) 
of these having a platelet count <100 × 109/L. 
Thrombocytopenia was uncommon in out-
patients but present in close to 30% of inpa-
tients, with a particularly high prevalence in 
patients admitted to medical wards (37.8%) 
(Table 1). Further information regarding the 
prevalence of thrombocytopenia among HIV-
positive patient subgroups is summarised in 
Table 3. Multivariate linear regression analy-
sis showed marginally significant indepen-
dent associations between the presence of 
thrombo cytopenia and both iAIDS (p=0.09) 
and exposure to ART (p=0.07), while no 
significant relationship was found between 
thrombocytopenia and VL (p=0.81). A Bon-
ferroni-adjusted Kruskal-Wallis analysis 
showed no significant difference in the plate-
let count between patients treated with the 
various antiretroviral regimens.
Leucocyte subset analysis
A differential white cell count was requested 
in 51/307 HIV-positive patients (16.6%), 
with median neutrophil, lymphocyte and 
monocyte counts of 3.42 × 109/L (IQR 2.23 - 
6.43), 1.34 × 109/L (IQR 0.67 - 2.08) and 
0.49 × 109/L (IQR 0.22 - 0.80), respectively. 
Neutropenia was present in 11/51 patients 
(21.6%), with 6/51 (11.8%) and 4/51 (7.8%) 
having neutrophil counts <1.5 × 109/L and 
<1 × 109/L, respectively. Lymphopenia was 
present in 18/51 patients (35.3%). Further 
information regarding the prevalences of 
neutropenia and lymphopenia in HIV-
positive patient subgroups is summarised in 
Table 3. On multivariate regression analysis, 
no significant relation ship was evident bet-
ween neutropenia and VL (p=0.23), ART 
exposure (p=0.15) or the presence of iAIDS 
(p=0.22), and a Bonferroni-adjusted Kruskal-
Wallis analysis showed no significant 
differences in the neutrophil count between 
patients treated with the various antiretroviral 
regimens.
Discussion
In this study conducted at the NHLS 
laboratory at CHBAH, 307 (30.5%) of the 
1 006 patients included were documented 
to be HIV-positive, of whom 63.2% had 
one or more cytopenia/s. These were signi-
ficantly more common among individuals 
who were inpatients or had iAIDS, but also 
occurred in close to 50% of outpatients and 
in >50% of those on ART. Anaemia was the 
most prevalent blood count derangement, 
being present in ~60% of all patients, 
~70% of ART-naive patients and ~80% 
of patients with iAIDS. The prevalence 
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in ART-naive patients was generally substantially higher than 
prevalences documented in previous studies from other parts 
of Africa, which ranged from ~20% to 50%.[6,7] With regard to 
other studies conducted among South Africans, the prevalence of 
anaemia among ART-naive patients was similar to that reported 
by Kerkhoff et al.,[10] (~70%), but higher than that documented by 
Takuva et al.[11] and Firnhaber et al.,[5] who both reported anaemia 
(Hb <10 g/dL) in ~20 - 25% of patients (as opposed to ~40% 
with Hb concentrations in this range in our study). The generally 
higher anaemia prevalence observed in this study compared with 
the majority of other African cohorts may be attributable to the 
fact that many of the previous studies in this field were performed 
in patients who were either enrolled in clinical trials or seen at 
outpatient ART clinics. In contrast, our study included patients 
hospitalised with HIV-related complications, among whom the 
prevalence of cytopenia/s would be expected to be higher than 
in more clinically stable patients. Nonetheless, the findings are of 
concern given the well-documented adverse prognosis associated 
with anaemia in HIV-positive patients.[2,12]
Multivariate regression analysis confirmed significant independent 
associations between anaemia and both male sex and iAIDS. 
Interestingly, these variables were not independently associated with 
severe anaemia, while a significant inverse relationship between 
the presence of severe anaemia and ART exposure was noted. This 
suggests that ART is protective against severe anaemia, regardless of 
immune status. Also of note was that the prevalence of anaemia was 
substantially lower in patients aged <18 years than in older patients, 
which may be due to the somewhat lower prevalence of iAIDS in 
these patients. Although certain antiretroviral agents (particularly 
Fig. 1. Comparison of Hb concentrations in patients (N=80) treated with 
various antiretroviral regimens. (TDF = tenofovir; PMTCT = prevention of 
mother-to-child transmission; D4T = stavudine; AZT = zidovudine; ABC = 
abacavir.)
18
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Table 2. Demographic and HIV-related details of the  
HIV-positive patients
Age, median (range) 36 yr (2 mo - 91 yr)
Age >18 yr, % 89.9
Male/female ratio 0.57:1
CD4 count (× 106/L), median (IQR)
Adults (n=218) 265.5 (114.8 - 467.8)
<18 yr (n=25) 549.0 (261.5 - 1 014.0
iAIDS, %
Adults (n=218) 39.5
<18 yr (n=25) 32.0
On ART, (%)
All (N=177) 83.1
Adults (n=154) 82.5
<18 yr (n=23) 87.0
Type of ART (N=80), n (%)
Zidovudine based 14 (17.5)
Stavudine based 16 (20.0)
Tenofovir based 29 (36.3)
Abacavir based 9 (11.3)
PMTCT 12 (15.0)
PMTCT = prevention of mother-to-child transmission.
Table 3. Prevalence of cytopenia in HIV-positive patient subgroups
All HIV+ patients,
n/N (%)
On ART,
n/N (%)
ART naive,
n/N (%)
iAIDS,
n/N (%)
ART naive  
with iAIDS,
n/N (%)
Any cytopenia 194/307 (63.2) 73/147 (53.7) 21/30 (70.0) 77/94 (81.9) 14/16 (87.5)
Anaemia
All 183/307 (59.6) 75/147 (51.0) 21/30 (70.0) 75/94 (79.8) 14/16 (87.5)
Severe 32/307 (10.4) 10/147 (6.8) 6/30 (20.0) 19/94 (20.2) 3/16 (18.8)
Moderate 91/307 (29.6) 29/147 (19.7) 12/30 (40.0) 64/94 (68.1) 10/16 (62.5)
Microcytic 33/183 (18.0) 12/75 (16.0) 4/21 (19.0) 16/75 (21.3) 3/14 (21.4)
Normocytic 122/183 (66.7) 44/75 (58.7) 15/21 (71.4) 48/75 (64.0) 10/14 (71.4)
Macrocytic 28/183 (15.3) 19/75 (25.3) 2/21 (9.5) 11/75 (14.7) 1/14 (7.1)
Thrombocytopenia 37/307 (12.1) 14/147 (9.5) 8/30 (26.7) 23/94 (24.5) 6/16 (37.5)
Neutropenia 11/51 (21.6) 3/23 (13.0) 1/5 (20.0) 5/28 (17.9) 1/5 (20.0)
Lymphopenia 18/51 (35.3) 4/23 (17.4) 2/5 (40.0) 15/28 (53.7) 2/5 (40.0)
HIV+ = HIV-positive.
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zidovudine) are reported to be associated with an increased risk 
of anaemia, the Hb level did not appear to be affected by the ART 
regimens used in this study. However, this finding should be treated 
with reserve, as the duration of ART exposure has not been taken 
into account, and the fairly limited data available about type of ART 
exposure may compromise the accuracy of these results.
Anaemia was microcytic in 18.0% of the HIV-positive patients and 
in 21.4% of the ART-naive patients with iAIDS. This is substantially 
lower than figures reported by Firnhaber et al.[5] in a study that 
compared the prevalence of various cytopenias in ART-naive patients 
from Africa, Asia and the Americas, where anaemia was found to 
be microcytic in 50% of cases.[5] Furthermore, in contrast to other 
studies, we found no significant difference in the MCV between 
males and females,[3] no difference in the prevalence of microcytic 
anaemia according to sex,[2] and a higher prevalence of anaemia in 
males than in females.[5,9] Collectively, these findings suggest that 
iron deficiency (the commonest cause of microcytic anaemia, and 
the form to which females are particularly predisposed) is not as 
highly prevalent in this population of patients as in other developing 
countries. Further investigation in this regard would be of interest.
Thrombocytopenia and neutropenia were present in 12.1% and 
21.6% of patients, respectively, with a platelet count <100 × 109/L in 
6.5% and a neutrophil count <1 × 109/L in 7.8%. These prevalences are 
somewhat higher than those reported elsewhere,[3-6] probably for the 
same reasons cited for the differences in the prevalence of anaemia. 
Thrombocytopenia was marginally associated with the presence of 
iAIDS and exposure to ART, while no significant association was 
evident between any HIV-related parameters and neutropenia.
HIV status was documented in close to 50% of the samples, 
with the highest rates of documentation in patients admitted to 
the medical wards and haematology/oncology units. In contrast, 
documentation rates were <50% in the other departments assessed, 
which may be due to point-of-care screening in some instances, or 
known results from testing at other sites. Nonetheless, these findings 
raise concern about the possibility that patients are generally only 
tested when they present with pathology that may be attributable 
to HIV infection. In the context of a community with a high HIV 
prevalence, failure to systematically screen all patients presenting to 
healthcare facilities (including those without HIV-related pathology) 
would appear to be a missed opportunity to improve early initiation 
of ART in otherwise asymptomatic patients. Further studies in this 
respect would be of value.
Among all the patients included, we found a documented 
HIV seropositivity rate of >30%, with >50% of the samples with 
documented HIV status being collected from HIV-positive patients. 
Over 20% of the samples included were collected from HIV-positive 
patients in the outpatient/PHC setting, which probably reflects an 
increase in demand for laboratory testing related to ART monitoring. 
With the subsequent change in CD4 threshold, which means that 
all HIV-positive patients are now offered ART, the demand for 
laboratory resources would be expected to have risen since these 
data were collected. Among inpatients, the highest seropositivity rate 
was seen in the medical wards, where close to 60% of the patients 
were HIV-positive. The HIV seropositivity rates in most of the 
other disciplines assessed was ~28 - 40%, the exception being in the 
paediatric wards, where the lower rate (<20%) testifies to the success 
of the prevention of mother-to-child transmission programme. As 
an FBC is performed at least once in most hospital inpatients, HIV 
seropositivity rates in the FBCs collected from this patient subgroup 
can be viewed as a surrogate for rates among hospital inpatients in 
general. As there is very little formal documentation of the latter in 
the literature, these findings are of interest and reflect the signifi cant 
burden of HIV infection among hospitalised state sector patients. 
However, these results should be treated with some degree of reserve 
given the fairly poor HIV documentation rate in most of the units 
(most notably in the obstetrics and gynaecology department). Since 
doctors are more likely to test for HIV when patients present with 
symptoms or possible complications of HIV infection, the prevalence 
rates reported here may be inflated. However, we found a similar 
seropositivity rate in the medical wards to that reported by Meintjes 
et al.,[13] who systematically tested patients admitted to the medical 
admission ward of a hospital serving a community in Cape Town 
of similar demographics to that served by CHBAH during 2012 and 
2013. Furthermore, HIV seropositivity rates in women attending 
antenatal clinics in the City of Johannesburg and the West Rand in 
2012 were 29.6% and 35.6%, respectively,[14] which are very similar to 
the rates we found in the non-medical disciplines. As sick patients 
with HIV are likely to seek medical assistance, it is not unexpected 
for hospital seropositivity rates to be higher than those of the 
surrounding apparently well community.
Study limitations
Limitations of this study include the limited data available on type 
and duration of ART exposure, which compromise accurate analysis 
in this respect. Differential white cell counts were available in <20% 
of patients, and the assessment for the prevalence of neutropenia 
is consequently weak. Furthermore, no information on transfusion 
history was available, which may affect the prevalence rates of 
cytopenias as well as assessment of their severity. Lastly, since this 
study was performed, ART guidelines have changed in respect 
of antiretroviral agents employed as well as the CD4 threshold 
for therapy initiation, which may have affected the prevalence 
of cytopenias to some extent. However, since cytopenias mainly 
occurred in patients with iAIDS (irrespective of ART), treatment of 
patients with normal CD4 counts is unlikely to have impacted on 
cytopenia rates in the short term. A follow-up study in this regard 
would be of interest.
Conclusions
More than 30% of the samples received for an FBC at the CHBAH 
NHLS laboratory were collected from HIV-positive patients, and the 
HIV seropositivity rate was >50% in those with documented HIV status. 
Among hospital inpatients, more than one-third were HIV-positive, 
with close to 50% of these being admitted to medical wards. Over 60% 
of the HIV-positive patients had one or more cytopenia/s, with anaemia 
being the most prevalent. Cytopenias were significantly more common 
among inpatients and individuals with iAIDS, but also occurred in close 
to 50% of outpatients and >50% of those on ART. These findings reflect 
the substantial impact of the HIV epidemic on state sector hospital and 
laboratory resources, particularly the haematology service.
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